Duloxetine 90mg Discontinuation Taper Schedule
For duloxetine 90 mg daily, taper gradually over at least 2-4 weeks minimum, reducing by 30 mg every 1-2 weeks (90mg → 60mg → 30mg → stop), though patients at higher risk for withdrawal may require much slower tapers over several months with smaller dose reductions.
Risk Assessment for Withdrawal
Before initiating any taper, assess the patient's risk for discontinuation symptoms:
High-risk factors include:
- Previous withdrawal symptoms with missed doses or prior taper attempts 1
- Duration of duloxetine use >1 year 2, 3
- Current dose above 60 mg daily 4
- History of anxiety or depression 5
Duloxetine specifically carries significant withdrawal risk—in clinical trials, 44.3% of patients experienced discontinuation-emergent adverse events (DEAEs) when stopped abruptly, compared to 22.9% on placebo 4. The most common symptoms are dizziness (12.4%), nausea (5.9%), headache (5.3%), paresthesia (2.9%), vomiting (2.4%), irritability (2.4%), and nightmares (2.0%) 4.
Standard Taper Schedule (Lower Risk Patients)
For patients without high-risk factors:
- Week 1-2: Reduce from 90 mg to 60 mg daily
- Week 3-4: Reduce from 60 mg to 30 mg daily
- Week 5-6: Reduce from 30 mg to stop
This represents approximately 33% dose reductions every 2 weeks 1, 4.
Extended Taper Schedule (Higher Risk Patients)
For patients with one or more high-risk factors, use a much slower approach 2, 3, 6:
- Month 1: 90 mg → 75 mg (reduce by ~17%)
- Month 2: 75 mg → 60 mg (reduce by 20%)
- Month 3: 60 mg → 45 mg (reduce by 25%)
- Month 4: 45 mg → 30 mg (reduce by 33%)
- Month 5-6: 30 mg → 20 mg → 10 mg (smaller decrements)
- Month 7: Consider extending intervals between doses before stopping
This hyperbolic tapering approach uses progressively smaller absolute dose reductions as you reach lower doses, which may better match receptor occupancy changes 2, 3, 7, 8.
Critical Implementation Points
Do not use alternate-day dosing when tapering duloxetine. Recent pharmacokinetic modeling demonstrates that dosing every other day causes pronounced receptor occupancy variation that significantly increases withdrawal risk, even at low doses 8. This common practice should be avoided.
Monitor closely: Follow up at least monthly during tapering, or every 2-4 weeks for high-risk patients 5, 3. Team members (nurses, pharmacists) can provide additional support through telephone or telehealth contact 5.
Distinguish withdrawal from relapse: Withdrawal symptoms typically emerge within 1-7 days of dose reduction and resolve within 7 days in 65% of cases 4. If symptoms persist beyond 2 weeks or worsen progressively, consider relapse rather than withdrawal 2, 3.
Adjust the taper based on symptoms: If clinically significant withdrawal symptoms occur, slow the taper rate, pause temporarily, or increase the dose slightly before attempting a slower reduction 5, 2, 3. The majority of duloxetine withdrawal symptoms are mild-to-moderate in severity 4.
Special Considerations
- Liquid formulations or compounded preparations may be necessary to achieve very small dose reductions (e.g., 1-5 mg decrements) in patients with severe prior withdrawal experiences 2, 3
- Maximize non-pharmacologic treatments for the underlying condition during tapering 5
- Never discontinue abruptly unless there are life-threatening adverse effects 1, 4
- Most withdrawal symptoms resolve within 7 days, but some patients experience protracted withdrawal requiring extended support 2, 3, 4
The evidence consistently shows that duloxetine, as an SNRI, requires gradual tapering to minimize discontinuation symptoms 9, 1, 9, 1. While the FDA label does not specify exact tapering schedules 10, clinical guidelines and research strongly support slow, individualized tapers based on patient risk factors and response 2, 3, 4, 6.